한글목차

세계 나노바디 시장 규모는 예측기간에 CAGR로 17.88%의 대폭적인 확대가 전망되고 있습니다. 만성 질환의 유행, 정밀의료에 대한 관심 증가, 나노 바디의 연구에 대한 관심의 확대가 시장 성장을 가속하고 있습니다.

지역 고찰

북미 시장은 2022년에 가장 큰 시장 점유율을 차지했습니다.

유럽 시장은 두 번째로 큰 시장 점유율을 차지했습니다. 독일 시장이 가장 큰 시장 점유율을 차지하고 프랑스 시장이 유럽에서 가장 빠르게 성장하고 있습니다.

아시아태평양 시장이 2023-2030년에 거대한 점유율로 성장할 전망입니다.

이 보고서는 세계의 나노 바디 시장에 대한 조사 분석, 시장 역학, 지역 및 부문 분석, 기업 프로파일 등을 제공합니다.

목차

제1장 주요 요약

제2장 시장의 소개

제3장 조사 방법

제4장 시장 역학

• 개요
• 성장 촉진요인
  • 만성질환의 유행
  • 정밀의료에 대한 수요 증가
  • 나노바디의 연구개발에 대한 투자 증가
• 억제요인
  • 제조상의 과제와 높은 생산 비용
• 기회
  • 나노 바디의 신용도 개발 확대

제5장 시장 요인 분석

• 밸류체인 분석
  • 연구개발
  • 제조
  • 유통 및 판매
  • 판매 후 모니터링
• Porter's Five Forces 분석 모델
• 세계의 나노 바디 시장에 대한 COVID-19의 영향
  • 공급망에 미치는 영향
  • 임상시험에 대한 영향
  • 수급에 미치는 영향

제6장 세계의 나노바디 시장 : 유형별

• 개요
• 모노스페시픽
• 멀티스페시픽

제7장 세계의 나노바디 시장 : 용도별

• 개요
• 치료
  • 암
  • 신경퇴행성 질환
  • 감염증
  • 기타
• 진단
  • 단백질 및 미생물 검출
  • 저분자 검출
  • 영상처리
• 연구

제8장 세계의 나노바디 시장 : 최종 사용자별

• 개요
• 제약 기업, 생명 공학 기업
• 연구소
• 기타

제9장 세계의 나노바디 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 기타 아시아태평양
• 기타 지역
  • 중동
  • 아프리카
  • 라틴아메리카

제10장 경쟁 구도

• 개요
• 경쟁 벤치마킹
• 세계 나노바디 시장의 주요 성장 전략
• 세계 나노바디 시장의 개발수의 주요 기업
• 주요 개발 분석
• 주요 발전과 성장 전략
  • 제품 출시/제품 승인
  • 합병 및 인수
  • 파트너십/협정/제휴
• 주요 기업의 매출 분석
• 주요 기업의 연구 개발 분석

제11장 기업 프로파일

• SANOFI
• MERCK KGAA
• BIOCYTOGEN
• PROTEINTECH GROUP, INC.
• NOVARTIS AG
• GENSCRIPT
• SENSEI BIOTHERAPEUTICS, INC
• BERONI GROUP
• EXEVIR BIO
• TAISHO PHARMACEUTICAL HOLDINGS CO., LTD
• DIOSCURE THERAPEUTICS SE

제12장 부록

영문목차

Market Overview

Nanobody Market is anticipated to register a significant market expansion at a CAGR of 17.88% during the forecast period. The rising pervasiveness of constant sicknesses, rising interest for accuracy medication, and expanding interest in nanobody innovative work are driving market development.

Nanobodies are little immunizer sections that enjoy a few upper hands over conventional antibodies, like more prominent dependability, better tissue entrance, and decreased immunogenicity. The rising commonness of immune system infections and other ongoing issues requests the revelation of fresher and more compelling nanobody-based drugs for their treatment. For example, in February 2019, the US Food and Medication Organization (FDA) endorsed Cablivi (caplacizumab-yhdp), the main nanobody-based medication of Sanofi S.A. (France), for grown-ups with gained thrombotic thrombocytopenic purpura (aTTP).

As indicated by the World Wellbeing Association (WHO), constant infections like malignant growth, cardiovascular sickness, and diabetes are answerable for 74% of all passings universally. The occurrence and predominance of these illnesses are supposed to keep on rising, driven by elements like maturing populaces, evolving ways of life, and expanding urbanization. Subsequently, the rising commonness of persistent infections, joined with the extraordinary benefits of nanobodies drives the market development.

Market Segmentation

Based on type the Nanobody Market is bifurcated into mono-specific and multi-specific. Based on application the market is divided into therapeutic, diagnostic, and research. The therapeutic segment is further segmented into cancer, neurodegenerative diseases, infectious diseases, and others. The Nanobody Market based on end user is classified into pharmaceutical & biotechnology companies, research laboratories, and others.

Regional Insights

The North America nanobody market represented the biggest market share in 2022. This is because of the great mindfulness related with nanobodies innovation in drug revelation and advancement to diminish the expense of creation in the North American area.

Europe nanobody market represents the second-biggest market share because of the presence of dynamic market players, developing nanobodies new businesses, and expanding predominance of illnesses, for example, irresistible, neurological, and disease. further, Germany nanobody market was ascribed to hold the biggest market share, and the France nanobody market is supposed to quickest developing market in the European locale.

The Asia-Pacific nanobody market is supposed to develop at a huge share from 2023 to 2030. This is because of the developing geriatric populace, expanding predominance of malignant growth and irresistible sicknesses, and further developing examination abilities in the Asia-Pacific locale.

The Remainder of the World is sectioned into the Center East, Africa, and Latin America. The nanobody market in the previously mentioned locales is probably going to observe development because of the rising pervasiveness of irresistible illnesses and the rising predominance of non-transferable sicknesses.

Major Players

Key Companies in the Nanobody Market include Sanofi (France), Merck KGaA (Germany), BIOCYTOGEN (US), Proteintech Group, Inc (US), Novartis AG (Switzerland), GenScript (US), Sensei Biotherapeutics, Inc (US), Beroni Group (Australia), ExeVir Bio (Belgium), Taisho Pharmaceutical Holdings Co., Ltd (Japan), and DiosCURE Therapeutics SE (Germany).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
  • 3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • 3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.4 FORECASTING TECHNIQUES
• 3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.5.1 BOTTOM-UP APPROACH
  • 3.5.2 TOP-DOWN APPROACH
• 3.6 DATA TRIANGULATION
• 3.7 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES
  • 4.2.2 RISING DEMAND FOR PRECISION MEDICINE
  • 4.2.3 INCREASING INVESTMENT IN NANOBODY RESEARCH AND DEVELOPMENT
• 4.3 RESTRAINTS
  • 4.3.1 MANUFACTURING CHALLENGES AND HIGH PRODUCTION COSTS
• 4.4 OPPORTUNITY
  • 4.4.1 GROWING DEVELOPMENT OF NEW APPLICATIONS OF NANOBODIES

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION AND SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL NANOBODY MARKET
  • 5.3.1 IMPACT ON SUPPLY CHAIN
  • 5.3.2 IMPACT ON CLINICAL TRIALS
  • 5.3.3 IMPACT ON DEMAND AND SUPPLY

6 GLOBAL NANOBODY MARKET, BY TYPE

• 6.1 OVERVIEW
• 6.2 MONO-SPECIFIC
• 6.3 MULTI-SPECIFIC

7 GLOBAL NANOBODY MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 THERAPEUTIC
  • 7.2.1 CANCER
  • 7.2.2 NEURODEGENERATIVE DISEASES
  • 7.2.3 INFECTIOUS DISEASES
  • 7.2.4 OTHERS
• 7.3 DIAGNOSTIC
  • 7.3.1 DETECTION OF PROTEINS AND MICROORGANISMS
  • 7.3.2 DETECTION OF SMALL MOLECULES
  • 7.3.3 IMAGING
• 7.4 RESEARCH

8 GLOBAL NANOBODY MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
• 8.3 RESEARCH LABORATORIES
• 8.4 OTHERS

9 GLOBAL NANOBODY MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 UK
  • 9.3.3 FRANCE
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 JAPAN
  • 9.4.2 CHINA
  • 9.4.3 INDIA
  • 9.4.4 SOUTH KOREA
  • 9.4.5 AUSTRALIA
  • 9.4.6 REST OF ASIA PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST
  • 9.5.2 AFRICA
  • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE BENCHMARKING
• 10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL NANOBODY MARKET
• 10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL NANOBODY MARKET
• 10.5 KEY DEVELOPMENT ANALYSIS
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
  • 10.6.2 MERGER/ ACQUISITION
  • 10.6.3 PARTNERSHIP/ AGREEMENT/COLLABORATION
• 10.7 MAJOR PLAYERS SALES ANALYSIS
• 10.8 MAJOR PLAYERS R&D ANALYSIS

11 COMPANY PROFILES

• 11.1 SANOFI
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 MERCK KGAA
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 BIOCYTOGEN
  • 11.3.1 COMPANY OVERVIEWS
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 KEY STRATEGIES
• 11.4 PROTEINTECH GROUP, INC.
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 KEY STRATEGIES
• 11.5 NOVARTIS AG
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTSS
  • 11.5.5 SWOT ANALYSIS
  • 11.5.6 KEY STRATEGIES
• 11.6 GENSCRIPT
  • 11.6.1 COMPANY OVERVIEWS
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 KEY STRATEGIES
• 11.7 SENSEI BIOTHERAPEUTICS, INC
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 SWOT ANALYSIS
  • 11.7.6 KEY STRATEGIES
• 11.8 BERONI GROUP
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 KEY STRATEGIES
• 11.9 EXEVIR BIO
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 KEY STRATEGIES
• 11.11 DIOSCURE THERAPEUTICS SE
  • 11.11.1 COMPANY OVERVIEW
  • 11.11.2 FINANCIAL OVERVIEW
  • 11.11.3 PRODUCTS OFFERED
  • 11.11.4 KEY DEVELOPMENTS
  • 11.11.5 KEY STRATEGIES

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS